Miravant Medical Technologies engages in the research and development of drugs and medical device products for the use in proprietary technologies for photodynamic therapy. The company is headquartered in Santa Barbara, California and currently employs 47 full-time employees. The drug and light procedures involve three components, the photoselective drugs, light producing devices and light delivery devices. The firm's products have been developed in-house and with outside collaborators and have been used in various clinical and preclinical investigations. Its most advanced drug, PHOTREX, generic name rostaporfin, has completed two Phase III clinical trials for the treatment of wet age-related macular degeneration (AMD). Miravant has branded its version of PDT technology with the trademark PhotoPoint.